Abstract
Exposure to seasonal allergens may contribute to spatiotemporal variations in asthma exacerbations. In the phase 3 NAVIGATOR study (NCT03347279), tezepelumab, reduced the annualized asthma exacerbation rate (AAER) versus placebo in patients with severe, uncontrolled asthma, across all seasons. This post hoc analysis evaluated the effect of tezepelumab on seasonal asthma exacerbations.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
